Does Mirabegron (Myrbetriq) Cause Postural Hypotension?
No, Mirabegron does not cause postural (orthostatic) hypotension based on FDA labeling and clinical trial data. In fact, the primary cardiovascular adverse effect of Mirabegron is hypertension, not hypotension.
Key Evidence from FDA Drug Label
The FDA label for Mirabegron explicitly lists hypertension as one of the most common adverse reactions (occurring in 7.5-11.3% of patients versus 7.6% in placebo), but orthostatic hypotension is not mentioned as an adverse reaction in the comprehensive safety data 1.
Adverse Reactions Profile:
- Most common adverse reactions (>2%): hypertension, nasopharyngitis, urinary tract infection, and headache 1
- Cardiovascular effects documented: hypertension, tachycardia (1.2-1.6%), palpitations, blood pressure increases 1
- Dizziness was reported in 2.7% of patients (versus 2.6% in active control), but this was not specifically attributed to orthostatic hypotension 1
Clinical Trial Data
In a pharmacokinetic interaction study examining Mirabegron with tamsulosin (an alpha-blocker known to cause orthostatic hypotension), researchers found:
- Small mean diastolic BP decreases of 2.1-4.2 mmHg were observed with combination therapy
- These changes were not accompanied by orthostatic symptoms or increases in positive orthostatic stress tests 2
- The study concluded there were no clinically relevant cardiovascular interactions 2
Important Clinical Distinction
This is a critical distinction from other medications used for overactive bladder:
- Alpha-blockers (like tamsulosin, used for urinary symptoms) are well-known to cause orthostatic hypotension 3
- Mirabegron works via a different mechanism (beta-3 adrenergic agonist) and has the opposite cardiovascular profile - it tends to increase blood pressure rather than decrease it 1
Clinical Implications:
Monitor for hypertension, not hypotension when prescribing Mirabegron:
- Check baseline blood pressure before initiating therapy 1
- Monitor blood pressure periodically during treatment, especially in patients with pre-existing hypertension 1
- The drug carries a specific warning about hypertension, not orthostatic hypotension 1
Guideline Context
While guidelines on orthostatic hypotension management recommend reviewing and potentially discontinuing medications that worsen orthostatic hypotension 4, Mirabegron would not be on this list of culprit medications. The 2024 ESC guidelines emphasize switching BP-lowering medications that worsen orthostatic hypotension to alternative therapies 4, but Mirabegron is not a BP-lowering medication - it's a BP-raising medication.
Bottom line: Mirabegron does not cause postural hypotension and should not be discontinued or avoided in patients with orthostatic hypotension concerns. The primary cardiovascular concern with this medication is hypertension, not hypotension.